Aardvark Therapeutics Faces Class Action Lawsuit Over Drug Safety Claims

The complaint centers on allegations that Aardvark Therapeutics violated the Securities Exchange Act by issuing materially false or misleading statements during its initial public offering and the subsequent months. According to the litigation filing, the company significantly overstated the clinical prospects and safety profile of ARD-101, causing financial harm to investors once the realities of the drug's development became public.

Shareholders who suffered losses during the specified class period are now eligible to seek appointment as lead plaintiff. While legal counsel from Schall, Brown & Schwartz LLP notes that lead plaintiff status is not a requirement to participate in a potential recovery, those interested in discussing their legal rights or potential involvement can contact Brian Schall or David Schwartz directly at their Los Angeles office. The case remains pending class certification, meaning investors currently remain absent class members unless they choose to take active steps to join the proceedings.